leadf
logo-loader
viewLexaria Bioscience Corp.

Full interview: Lexaria Bio Science files patent for technology to treat infection disease including Corona

Lexaria Bioscience (CSE: LXX-OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to discuss the company has filed a patent for their DehydraTech technology for the delivery of antiviral drugs.

Bunka telling Proactive this technology would potentially be used to improve treatment options for viral infectious diseases including COVID-19, MERS, SARS, influenza, herpes, hepatitis and AIDS.

Quick facts: Lexaria Bioscience Corp.

Price: 0.36 CAD

CSE:LXX
Market: CSE
Market Cap: $32.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lexaria Bioscience signs R&D agreement with British American Tobacco

Lexaria Bioscience (CSE: LXRP-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to share news the company has signed a deal with British American Tobacco Limited. That company has products sold in over 11 million locations across more than 180 countries. Bunka telling...

3 weeks, 4 days ago

2 min read